Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
Are Investors Undervaluing Global Partners (GLP) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.
Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy
Omada Health NASDAQ: OMDA highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships.
GLP Q2 Earnings Call Flags Hedging Costs Amid Strong Fuel Margins
Global Partners flags higher hedged-inventory carrying costs from steep backwardation, even as strong fuel margins lifted second-quarter product margins.
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)
Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 obesity drug space and key data catalysts approach. VKTX's lead asset VK2735 is in large Phase 3 VANQUISH trials, but efficacy expectations are high, and prior data is limited to a small, short Phase 2 study. A pivotal Q3 catalyst is the maintenance dosing study for VK2735; results could drive price volatility and influence funding needs amid high cash burn.
Global Partners LP Common Units (GLP) Q2 2026 Earnings Call Transcript
Global Partners LP Common Units (GLP) Q2 2026 Earnings Call Transcript
Amazon.com said patients with Medicare Part D prescription plans now have access to certain GLP-1 weight-loss medications through Amazon Pharmacy
Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo will be available at a cost of $50 a month.
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.
GLP-1's Drove Eli Lilly's Record-Breaking Q2, but AI Will Be Its Future
The market has spent the past two years treating pharmaceutical stocks like a referendum on GLP-1 drugs.
Eli Lilly Stock Rises as GLP-1 Demand Drives Beat-and-Raise
Eli Lilly (NYSE:LLY) is higher ahead of the open, up 4.8% to trade at $1,169, after the pharmaceutical giant reported second-quarter earnings and revenue that topped Wall Street's expectations, while raising its full-year 2026 revenue guidance.
